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Abstract 
The aim of this study is to review the best clinical evidence concerning the use of 
dexamethasone intravitreal implant in diabetic macular edema (DME). Main outcomes 
assessed included change in best corrected visual acuity (BCVA) and change in central 
macular thickness (CMT). Main adverse events, such as, cataract and increased 
intraocular pressure (IOP) were evaluated. This article reviews six randomised clinical 
trials (RCTs) searched through several databases. Dexamethasone intravitreal implant 
are effective compared to laser, anti-VEGF and placebo, and seems to be more effective 
in combination to anti-VEGF and laser in lowering CMT. It was associated with 
increased incidence of cataracts (after the first year of treatment) and IOP rise but 
it required fewer injections and, thus, a final lower cost. This implant may be a 
promising treatment option for eyes with persistent DME and can be a treatment 
option in eyes that do not respond to anti-VEGF therapy, pseudophakic eyes or in those 
eyes about to undergo cataract surgery, in vitrectomized eyes or in patients who have 
barriers to monthly treatment regimen. 
Resumo 
O objetivo deste estudo é providenciar a melhor evidência cientifica relativa ao uso do 
implante intraocular de dexametasona, no edema macular diabético. Os principais 
parâmetros avaliados foram a acuidade visual e a espessura macular central. Os 
principais efeitos adversos, como a catarata e o aumento da pressão intraocular, foram 
igualmente avaliados. Este artigo analisa seis estudos randomizados e controlados, os 
quais foram retirados de várias bases de dados cientificas. O implante intraocular de 
dexametasona demonstrou ser efetivo comparativamente à terapia com laser, agentes 
anti-VEGF e placebo, e demonstrou, inclusivamente, ser mais efetiva em combinação 
com agentes anti-VEGF e laser na diminuição da espessura macular central. No entanto, 
esta terapia está associada a um aumento da incidência de cataratas (após o primeiro ano 
de tratamento) e a um aumento da pressão intraocular, porém, requer um número menor 
de injeções, o que determina, um custo final inferior. Este implante pode ser 
considerado uma alternativa inovadora e uma opção possível para olhos que não 
respondem a terapia com agentes anti-VEGF, olhos pseudofáquicos ou com cirurgia de 
catarata programada, olhos vitrectomizados ou em pacientes que não suportam o regime 
de tratamento mensal.   
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Abbreviations: BCVA (best corrected visual acuity); BRVO (branch retinal vein 
occlusion); CRVO (central retinal vein occlusion); CMT (Central Macular Thickness); 
CRT (Central Retinal Thickness); DDS (drug delivery system);  Dex (dexamethasone); 
DME (diabetic macular edema); DR (diabetic retinopathy); ETDRS (Early Treatment 
Diabetic Retinopathy Study); EU (European Union); FA (fluocinolone acetonide); IOP 
(intraocular pressure); ME (macular edema); PLGA (poly D,L-lactide-co-glycolide); 
RCT (Randomized Clinical Trial); RVO (retinal vein occlusion); TA (triamcinolone 
acetonide), VA (Visual Acuity); VEGF (vascular endothelial growth factor).  
 
Introduction 
The major cause of  impaired vision in patients between 25 and 74 years of age is 
Diabetic ocular disease.[1] Visual impairment is mainly originated by complications 
related to  diabetic maculopathy and neovascularization, as retinal detachment or 
neovascular glaucoma. Causes of visual impairment and blindness in developing 
countries (such as cataracts and trachoma) are declining, but the prevalence of Diabetic 
retinopathy (DR) is growing.[2] Diabetic macular edema (DME) affects around 21 
million people worldwide. [3] 
The 10-year incidence of DME was different among different types of diabetes or 
insulin patients use, with 20.1% in patients with type 1 diabetes, 25.4% in patients with 
type 2 diabetes who used insulin and 13.9% in patients with type 2 diabetes who did not 
use insulin. [4] 
Risks factors comprise the type of diabetes, level of glycemic control and associated 
conditions such as hypertension, dyslipidemia, smoking, nephropathy and pregnancy. 
Thus, the several preventive and therapeutic interventions, such as intravitreal 
pharmacological therapies, are crucial to minimize the morbidity associated with DR.  
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What is DME? 
Macular Edema (ME) can occur at any stage of DR and involve both the macular region 
and peripheral retina. Clinically significant DME is characterized by capillary leakage, 
fluid accumulation, and macular thickening within 500 microns of the fovea, circinate 
hard exudates within 500 microns of the fovea if associated with adjacent retinal 
thickening, or one or more areas of retinal thickening at least 1500 microns in diameter 
that is within one disc diameter (1500 microns) of the fovea. DME leads to breakdown 
of the blood retinal barrier [5], and consequent visual acuity (VA) loss. [6] 
The pathophysiology of ME is complex and involves an increased hydrostatic venous 
pressure, inflammation, endothelial dysfunction, and increased vascular permeability 
factors, such as vascular endothelial growth factor (VEGF) with a range of factors 
implicated. [7]   
Through several years, the investigation of the pathophysiology of ME led to a better 
understanding of the role of inflammatory mediators that are responsible for the 
accumulation of fluid within the retina and cellular damage. [8] Several factors are 
involved in the inflammation derived from DME and ME secondary to RVO, including 
the expression of multiple inflammatory factors like vascular endothelial growth factor 
(VEGF), intercellular adhesion molecule-1, interleukin-6, and monocyte chemotactic 
protein-1, and also leukostasis and alterations in endothelial tight junction proteins.[5] 
The inflammation magnitude in the ME progressively increases as long as time went by.  
For the past decades, laser photocoagulation has been the treatment of choice for DME, 
however in recent years, the treatment of clinically significant ME has been a rapidly 
evolving area and several alternative options have emerged. Today, intravitreal anti-
VEGF pharmacotherapy is the considered the first-line treatment but other options are 
available as, vitreoretinal surgery or intravitreal corticosteroids, including 
dexamethasone (Dex).  
Roll of Inflammation and Corticosteroids 
 
Corticosteroids can help to reduce many of the inflammatory processes in the 
development of ME, since they are potent and selective agonists of the glucocorticoid 
receptor, which are expressed in ocular tissues and are sensitive to corticosteroids in 
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ophthalmic treatments, as Dex, triamcinolone acetonide (TA), and fluocinolone 
acetonide (FA). [9] [3] 
Several mechanisms have been proposed. They have potent anti-inflammatory effects 
by expression of several anti-inflammatory proteins, including IL-10, adenosine, and 
IκBα, the natural inhibitor of NFκB. [3] They also reduce vascular permeability and 
promote retinal fluid clearance through their effects on transcellular aquaporin-4 
(AQP4) and potassium channels, the two main channels controlling retinal fluid 
movement on retinal Müller cells. [3] 
At the outer blood retinal barrier, corticosteroids keep tight junction integrity and they 
stabilize the existing retinal vasculature, have antiangiogenic effects by suppressing the 
production of paracrine angiogenic factors, and also, reducing the growth of new blood 
vessels. [3] They can also inhibit fibrin deposition and leukocyte trafficking, repress 
homing and migration of inflammatory cells, and inhibit the synthesis of prostaglandins 
and other cytokines.[9]  
In the past, intraocular or periocular corticosteroids administration produced just a 
transient treatment effect. As a result, repeated injections were necessary. However, 
Ozurdex
®
 deliver Dex over an extended time frame, with less injections and favorable 
outcomes (mean VA and CRT). Nevertheless, it is also associated with high rates of 
cataract formation and glaucoma. [8]  
 
Use of Ozurdex
®
 
Ozurdex
®
 is approved by the United States Food and Drug Administration and by the 
European Medicines Agency, and is already available throughout the European Union 
as a treatment licensed for the treatment of ME following branch or central retinal vein 
occlusion (BRVO or CRVO) and treatment of non-infectious uveitis affecting the 
posterior segment of the eye since September 2010 and for DME since July 
2014.[10][11] [12] 
Ozurdex
®
 is an intravitreal implant containing 0.7 mg (700 mcg) of Dex in the 
Novadur
® 
solid polymer biodegradable, slow-release drug delivery system (DDS) that is 
injected through the pars plana by a customized, single-used 22-gauge applicator. 
[7][12] The Novadur
®
 system contains poly D,L-lactide-co-glycolide polymer matrix 
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without preservative witch slowly degrades to lactic acid and glycolic acid and is 
designed to deliver drug to the retina over a period of up to 6 months after intravitreal 
injection.[12] The intravitreal administration bypasses the blood–retinal barrier with 
minimal systemic absorption, which results in continuous high concentrations of Dex in 
the retina and vitreous during the first 2 months after the injection, and lower 
concentrations are sustained up to 6 months. By avoiding the peak vitreous drug 
concentrations produced by intermittent bolus corticosteroid injections and the need for 
frequent injections, the implant reduce the risk of adverse steroid-associated ocular 
effects (cataract, increased intraocular pressure, and glaucoma) and injection-related 
complications (lens injury, retinal detachment, and infectious endophthalmitis). [3] 
The intensity of pain associated with the insertion procedure is not substantially 
different from that produced by intravitreal anti-VEGF treatment, which use a 28 to 30 
gauge needle. The implant is biodegradable and subsequent implant(s) can be inserted 
without the need for surgical removal of the previous implant. The impact velocity of 
the Dex intravitreal implant, using the applicator, is insufficient to cause retinal damage 
proved by high-speed, real-time photography of the injection procedure.[3] The 
injection procedure has some complications, such as accidental lens touch, and splitting 
or fracture of the implant, and some in situ complications associated with migration into 
the anterior chamber, potentially leading to development of corneal edema.[3] 
Intravitreal injections have been associated with endophthalmitis, eye inflammation, 
increased intraocular pressure (IOP), and retinal detachment. Patients should be 
monitored following the injection. [10] 
Prophylactic treatment of ME that is not clinically important is not recommended, but 
once DR progresses to macular edema, treatment is indicated to slow the rate of vision 
loss and improve the long-term prognosis.[3] Treatment of DR is directed both at 
prevention (strict glycemic control early in the course of diabetes) and at treatment of 
established disease.[13] 
For two decades, laser photocoagulation has been the mainstay of treatment for DME 
but even if it was useful in preserving vision, it was of limited effect in restoring lost 
vision, once lost.[14] In most patients with clinically significant ME, anti-VEGF agents 
are actually first-line therapy in order to their established efficacy, less incidence of 
complications, and good ability of administration. However, corticosteroids comparable 
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to laser, seems to be less aggressive to retina, and comparable to anti-VEGF agents, it 
had a long-term effect, and provide less interventions. [14][15] 
 
Purpose 
 
The aim of this paper is to review the best evidence supporting the use Ozurdex
®
 for the 
treatment of DME. This study focuses on the current evidence for the use of  Dex versus 
anti-VEGF drugs and/or laser, as assessed by change in best corrected visual acuity 
(BCVA), central retinal thickness (CRT), and their adverse events (cataract and 
increased IOP). 
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Methods 
This review was limited to RCTs looking at the use of dexamethasone intravitreal 
implant and eligibility criteria are described in flow-diagram 1.  
The literature search was performed from August 2015 to  February 2016 using the 
databases Medline, EMBASE, Cochrane Library, World Health Organization 
International Clinical Trials Registry Platform, clinicaltrials.gov and UpToDate.  
The search terms to search all trials registers and databases were: anti-VEGF, 
corticosteroids, dexamethasone, diabetic macular edema, laser photocoagulation, 
Ozurdex
®
. 
To be included, studies (1) had to be Randomised Clinical Trials, (2) had a minimum 
follow-up of 6 months and (3) had to comprise at least two treatment arms or sham 
control, including Dex as active comparator of interest. Studies were excluded if they 
(1) had no control group, (2) assessed the effect of the mentioned treatments in ME due 
to other retinal diseases besides DME (3) were combined with a surgical intervention or 
(5) published studies in languages other than English.  
Data were extracted by three authors (MC, DC, MS) and checked by two of them (MC 
and MS). Search results were screened by two independent authors (MC and MS).  
Disagreements were resolved by discussion between the two review authors (MC and 
MS). 
Information was extracted from each included trial on: (1) type of outcome measure 
(mean change in BCVA, assessed in terms of Early Treatment Diabetic Retinopathy 
Study (ETDRS) letters; mean decrease CRT; safety analysis of adverse events, as 
cataract and increased IOP); (2) type of intervention ( dexamethasone intravitreal 
implant, anti-VEGF agents, laser therapy); (3) trial’s inclusion and exclusion criteria.  
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Flow-diagram 1. Information through the different phases of this review  
The RCTs evaluated in this review were: (1) Three-Year, Randomized, Sham-
Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic 
Macular Edema (MEAD study); (2) A Randomized Clinical Trial of Intravitreal 
Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema: The 
BEVORDEX Study; (3) Dexamethasone Intravitreal Implant in Combination with Laser 
Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema (PLACID 
STUDY); (4) A prospective randomised controlled clinical trial comparing a 
combination of repeated intravitreal Ozurdex
®
 and macular laser therapy versus macular 
laser only in centre-involving diabetic macular edema (OZLASE study); (5) 
Randomized Controlled Trial of an Intravitreous Dexamethasone Drug delivery system 
in Patients With Diabetic Macular Edema (Haller et al); (6) A 12-Month, Single-
Masked, Randomized Controlled Study Of Eyes With Persistent Diabetic Macular 
Edema After Multiple Anti-Vegf Injections To Assess The Efficacy Of The 
Dexamethasone-Delayed Delivery System As An Adjunct To Bevacizumab Compared 
With Continued Bevacizumab Monotherapy (Maturi et al).   
 
 
 
94 articles identified through 
database searching  
Exclusion of  studies 
which are not RCTs and 
were not  related to 
DME (n=44)  
44 of records excluded by primary 
outcomes and after subanalysis removed 
6 studies included in analysis  
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Results  
RCTs were analyzed concerning type of study, sample, intervention and control group. 
Data extracted from the RCTs concerning primary outcomes - BCVA, CRT- and 
adverse events - cataract incidence and IOP elevation - are summarized in tables. 
Primary outcomes 
 Visual Acuity  
Table 1 summarizes inclusion and exclusion criteria of RCTs (annexed document) and 
table 2 overviews the results of BCVA.  
Dose and Sham Control  
Two included trials compared two doses of Dex administered as an intravitreal implant 
(0,7 mg and 0,35 mg) with sham control: MEAD study and Haller.  
The baseline characteristics of the studies are reasonably similar, except in number of 
enrolled patients (1048 patients were enrolled in MEAD study and 315 patients in 
Haller et al) and follow-up period (3 years versus 180 days), however, the comparable 
results was from baseline to the studies end.  
In MEAD study [5], the percentage of patients who achieved  ≥15 letter improvement in 
BCVA from baseline at study end (3 years) was superior with Dex 0,7 mg than Dex 
0,35 mg and sham  (22,2%, 18,4% and 12,0% respectively) with statistical significance 
(P ≤ 0.018).  The mean average change in BCVA from baseline during the study was 
3.5 letters, 3.6 letters and 2.0 letters (Dex 0,7 mg, Dex 0,35 mg and sham, respectively).  
In spite of follow-up was 3 years, the greater effect of Dex implant in percentage of 
patients with a ≥15 letter improvement in BCVA from baseline were observed as early 
as day 21 between each Dex group (P ≤ 0.003) and at the majority of visits.  
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Subgroup analysis revealed that BCVA results varied between pseudophakic and phakic 
eyes. The mean average BCVA improvement with Dex implant (either 0,7 mg or 0,35 
mg) was greater until the time of cataract development. The mean number of phakic 
eyes and pseudophakic eyes, enrolled in study, was 257,6 and 91,6 respectively. 
Cataract formation changed the improvement of BCVA in phakic eyes. MEAD study 
described results in a subanalysis group of pseudophakic eyes (gain of ≥ 15 letters in 
BCVA from baseline at the study end of pseudophakic eyes): 23.3% in Dex 0,7 mg, 
15,9 % in Dex 0,35 mg and 10,9% in sham group.  
In the overall population, the mean change in BCVA decreased after 9 months, but in 
pseudophakic population these results were more stable for 3 years. After cataract 
surgery, the improvement in vision was restored in phakic eyes and the results from 
baseline at study end was equivalent in both eyes, pseudophakic and phakic eyes.  
Haller et al [16] demonstrated the percentage of patients who achieved  ≥10  letters of 
improvement in BCVA results at day 60, 90 and 180, but the percentage of patients who 
achieve ≥15 letters are shown in a figure, hence, the percentage (p values are not 
estimated) were estimated throw image analysis. The estimated percentage of patients 
who achieve ≥15 letters at day 180 were, approximately, 14% (Dex 0,7 mg), 9% (Dex 
0,35mg) and 7% (sham; P=0.22 Dex 0,7 mg versus sham). At day 90, were 
approximately 11% (Dex0,7 mg), 5% (Dex0,35mg) and 2% (sham; P= 0.05 Dex0,7 mg 
versus sham). The p values, at day 90, demonstrate that the difference between the Dex 
0,7 mg and sham group was statistically significant. This difference was not significant 
at day 180.  
In this study, cataract formation did not affect BCVA, due to the short follow-up period.    
Bevacizumab 
The studies included in this paper which compared Dex to bevacizumad are Maturi et al 
and Bevordex study. The aim of these RCTs was to determine if Dex implant 0,7 mg 
combined with bevacizumab 1,25 mg (anti-VEGF agent) provides greater benefit than 
bevacizumab alone and to determine head-to-head the effect of Dex implant opposed to 
bevacizumab (Maturi et al and Bevordex, respectively). Baseline characteristics of the 
groups are reasonably similar, even though, Bevordex study had involved almost twice 
the number of patients compared to Maturi.   
14 
 
In Maturi et al [17], the mean VA changes from baseline to 12 months and the average 
time to achieve ≥15 letter improvement, were similar between two groups. The 
improvement in VA was fairly stable in the first 9 months, and then slowly improved 
until month 12.   
Before study, the eyes enrolled had  received bevacizumab injections. After enrollment 
in study, it were randomly assigned to receive combination therapy (bevacizumab plus 
Dex) or bevacizumab monotherapy. The eyes that received combination treatment and, 
simultaneously, had received the greatest number of injections (previously), acquired a 
greater improvement in VA comparable to eyes that received monotherapy and the same 
previously injections.   
Bevordex study [18] demonstrated an improvement in BCVA of ≥10 letters from 
baseline by the 12 month visit of 40% in bevacizumab group compared with 41% of 
Dex group. An improvement in BCVA of ≥15 letters from baseline by the 12 months 
was 31% (bevacizumab group) and 10% (Dex group). The mean improvement in 
BCVA was 8.9 letters (bevacizumab group) and 5.6 (Dex group), but the difference was 
not statistically significant (P =0.24).   
Cataract formation conditioned a loss of ≥10 letters in 11% in Dex implant eyes, but 
none in the bevacizumab group. The difference between the two groups was not 
statistically significant and the mean number of injections over the 12 months was 8.6 
and 2.7, for bevacizumab and Dex group, respectively. The percentage of patients that 
preferred dexamathesone implant was 46% comparable with 33% of patients that 
preferred bevacizumab implant.   
Laser therapy 
The studies witch evaluated Ozurdex
®
 0,7 mg combined with Laser therapy compared 
with laser monotherapy are OZLASE study and PLACID Study.  
OZLASE Study had failed to prove an improvement in mean change in BCVA at 56 
weeks in the combination group (table 2), despite of frequent injections (mean of 3.5 
Ozurdex
®
 injections in the combination arm). [19] 
PLACID Study compared 6 monthly Dex implant 0,7 mg combined to laser therapy 
versus laser therapy alone, with a mean of 1.67 implants used over a period of 12 
15 
 
months. From month 1 to 9, the study proved a significantly improvement in BCVA in 
the combination arm, mainly among patients who received Dex implant before laser 
treatment compared with patients who received the sham injection (23.2% versus. 
11.9%; P = 0.035). However, at study end (month 12), PLACID did not prove 
significant different in percentage of patients who gained ≥10 letters in BCVA, between 
the two treatment groups. 
 
 
 Central retinal thickness 
The outcome results and baseline characteristics are shown in table 3.  
Dose and sham control 
MEAD study [5], demonstrated a significantly improvement in mean average reduction 
in CRT, during the study, in eyes treated with Dex implant 0.7 mg and 0.35 mg 
compared to sham. Eyes treated with Dex implant, despite cataract and vision loss,  
showed a decrease in CRT. After cataract surgery, CRT increased in sham group but did 
not increase in Dex implant groups.  Notably, an increase  in CRT after cataract surgery 
was observed  in the sham group but it wasn’t detected in the Dex implant groups. 
Haller et al [16] demonstrated, at day 90, a significantly improvement in mean change 
of macular thickness in eyes which had received Dex implant 0.7 mg comparable with 
sham. A significant improvement in fluorescein leakage was observed in the same 
group. In both parameters (macular thickness and fluorescein leakage), there were a 
greater response in eyes treated with Dex implant 0.7 mg than 0.35 mg and sham group, 
suggesting a dose-response relationship. 
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Bevacizumab 
Baseline characteristics in Maturi [17] revealed lower CRT in eyes of the combination 
group than bevacizumab treatment (344 µm versus 423 µm).  
During 12 months, the mean changes of CRT in combination group, had an irregular 
configuration, with peaks that corresponded to Dex implant injections at month 1, 5 and 
9. In the same treatment group, the average CRT significantly decreased after the first 
Dex injection through month 3, and increased until month 5. The irregular trace of these 
results, became more regular, with moderate peaks, after second and third injections. In 
bevacizumab treatment group, the mean changes in CRT were relatively stable, but 
declined progressively between month 8 and 12. In conclusion, results in table 3 
expressed a greater mean reduction in central subfoveal thickness in combination group 
compared to bevacizumab group, from baseline until month 12 (-45 µm and -30 µm, 
respectively).  
Bevordex study [18], achieved the same conclusion than Maturi et al, with a mean 
change in CMT of -122 μm  for the bevacizumab group and -187 μm for Dex implant 
group. In Dex treatment group, the CMT peaked at month 4 and 8. The number of 
injections in the Dex implant group and in the bevacizumab treatment group was 2.7 
and 8.6 injections, respectively.  
Laser therapy  
OZLASE study [19], at 56 weeks, showed a decrease in central subfield thickness of 
−113 μm  in combination group and −17 μm in laser therapy alone (p<0.001), revealing 
a better result for the combination group.  
PLACID Study [20], provided results about CRT and area of diffuse vascular leakage, 
measured angiographically. The decrease in CRT was significantly greater in the 
combination group compared to laser therapy alone group at 4 of the 8 follow-up visits, 
but there was no difference in the mean reduction in retinal thickness at month 6 or 12. 
However, changes in area of vascular leakage were statistically significant at all time 
points, during the study (P≤0.007). 
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Adverse Events  
The most prevalent adverse events recognized in RCTs were cataract events and rises of 
IOP, hence, the following results focuses only this adverse events.  
 Cataract  
The development of cataract were noted in almost studies, after the first year, and it  
changed results of vision improvement.  
Dose and sham control 
MEAD study [5] verified that rate of cataract formation was higher in eyes that received 
Dex 0.7 mg and 0.35 mg implants comparable with sham (67.9, 64.1 and 20.4 
respectively). This study divided the safety analyze between two groups: pseudophakic 
and phakic eyes. Cataract formation was associated with mean improvement in BCVA, 
as discussed above. Pseudophakic eyes treated with Dex implant had a stable VA gain, 
while phakic eyes had a decrease in VA at month 15, due to cataract formation. Cataract 
surgery was perfomed between month 18 and 30, and after surgery, improvement in 
BCVA was restored in Dex implant groups. An increase in CRT was only observed in 
sham group and there was no increase in CRT in Dex 0.7 mg or 0.35 mg treatment 
groups.     
Haller [16] reported no significant difference in cataract formation between study 
groups. However, follow-up period of this study was only 6 months and there was prior 
cataract extraction in some patients (table 4). 
Table 4. -Prior cataract extraction- data from Haller et all.  
 
 
 
Dex 0.35 mg  (n=57),  
n (%) 
Dex 0.7 mg (n=57) ), 
 n (%) 
Observation (n=57), 
 n (%) 
Prior cataract 
extraction 
11 (19) 12 (21) 11 (19) 
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Bevacizumab 
In Maturi study [17] the development of cataract was detected in nine eyes. Decreases 
in vision gain, in the combination group, was associated with progression of cataract, as 
described in MEAD study.  
Bevordex study [18], such as studies described above, proved that cataract formation 
was higher with Dex implant comparable to bevacizumab implant (13% versus 4.8%), 
and it was associated to a higher rate of cataract surgery in the same group (6.5% versus 
2.4%). Cataract formation rates increased in the second year of treatment, with 
intravitreal steroid therapy, as seen in other studies. In Bevordex study, loss of more 
than 10 letters in BCVA was associated with cataract formation in Dex implant group 
(11% in Dex implant group versus 0% in bevacizumab implant group). Although rate of 
cataract formation was higher in Dex implant group, the mean gain in BCVA was not 
statistically significant different between two groups.   
Laser therapy 
In OZLASE study [19] phakic eyes treated with combination treatment experienced a 
higher rate of cataract formation than laser therapy alone (21 patients and 4 patients, 
respectively) and ,also, a higher rate of cataract surgery (33%). After cataract surgery, 
eyes in the combination group, showed an improvement in VA at week 56. OZLASE 
study proved similar cataract-related confounding effects than MEAD study. Despite 
OZLASE demonstrated no difference in BCVA between the combination group and 
laser therapy alone arm at  week 56, it proved a significant reduction in macular 
thickness in combination arm.  
PLACID Study [20] proved that, phakic eyes treated with Dex implant plus laser 
therapy, obtained a higher rate of cataract formation comparable to eyes treated with 
laser therapy alone (22.2% and 9.5%, respectively). Nevertheless, rates of cataract 
surgery were not different between treatment groups (3.2% and 3.9%). 
 Increased intraocular pressure 
Dose and sham control:  
In MEAD study [5], there was a transient IOP increase, which peaked 2 months after 
implant injection and returned to baseline levels 6 months after each intervention. 
23 
 
Increases in IOP were controlled with medications, and no patient underwent removal 
of the implant to control IOP. Increases in IOP of 35 mmHg or more, were confirmed in 
6.6 % of eyes treated with Dex0.7 mg, 5.2% of eyes treated with Dex0.35 mg. One eye, 
in each group of Dex treatment, needed glaucoma filtering surgery. There was no 
cumulative effect of Dex implants, since IOP did not increased after subsequent 
treatments or in year 2 or 3, and the rate use of IOP lowering medications remained 
stable during the study.  
Haller [16] described an increased IOP in eyes treated with Dex implant. An IOP of ≥25 
mmHg up to day 90 and throw day 180 was seen in Dex treatment groups, and none in 
the observation group, which mostly occurred during the first week of the study. Unlike 
MEAD study, no eye required laser or filtering surgery to control IOP, and increases in 
IOP were controlled with IOP lowering drugs.  
Bevacizumab  
Both bevacizumab comparative studies demonstrated that eyes treated with Dex 
developed higher rates of increased IOP. In Maturi study [17], one of the patients 
developed increased IOP in both eyes, but only one eye received Dex implant.  
In Bevordex study [18], throughout the 12 month study, 12 eyes increased IOP of ˃ 25 
mmHg at least once, and all were treated with Dex implant. In the same study, one eye 
from each group, needed laser trabeculoplasty to control IOP. Any case of filtering 
surgery to control IOP was described in Maturi [17].  
Laser therapy 
Comparative RCTs between Dex implant plus laser therapy and laser therapy alone, 
demonstrated that eyes in the first group has higher rates of increased IOP and in all 
cases, the elevations in IOP were managed with IOP-lowering medication or 
observation. In both studies, no surgery for elevated IOP were required. 
OZLASE study [19] described that the increased frequency of Dex implant injections, 
did not result in higher intraocular concerns.  
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Discussion 
In this study, the effects of Ozurdex
®
 were evaluated for the treatment of DME. The 
results of this six RCTs proved the benefit of Ozurdex
®
 by improving VA and reducing 
CMT in patients with DME.  
MEAD and Haller provided improvement in vision (at year 3 and day 90, respectively), 
despite VA was confounded by cataract in phakic patients after the first year only in 
MEAD study, since follow-up period of Haller was only 180 days and cataract 
formation was determined in studies witch follow-up was upper than 12 months. 
Although comparative studies between Bevacizumab and Dex (Maturi and Bevordex) 
showed no statistically significant difference in VA’s results between the two groups, 
the CRT had greater decreases with Dex implant and provided less injections than 
Bevacizumab implant (8.6 versus 2.7 injections - Bevordex Study; combined group 
received three fewer bevacizumab injections than those in the monotherapy group – 
Maturi study). There was a dose-response relationship, since the response of 0.7 mg was 
greater than the 0.35 mg Dex implant, in MEAD and Haller studies.   
Mathew showed that Ozurdex
®
 not only is an effective therapy in primary outcomes 
(visual function and macular thickness) but also reduces leakage in the macula. [21] The 
retreatment time is indicated in 20 weeks (and shorter than 6 months), since represent a 
reasonable time in terms of effectiveness (VA and CRT), appearing of side-effects, and 
clinical efficacy of Ozurdex
®
 peaks at 12- 16 weeks. [21] [20] 
Although earlier studies, such as the MEAD study, included patients with persistent 
EMD after laser treatment, more recent studies include patients who have been 
refractory to laser therapy and anti-VEGF agents and thus, VA is unlikely to improve 
despite an amelioration of macular edema. [22] 
Laser studies (OZLASE and PLACID) did not prove an improvement in mean change 
in BCVA in Dex implant plus laser group, despite showing an improvement in 
anatomical outcome in the combination group. Nevertheless laser therapy can be used 
selectively for focal lesions and it is an important comparator. [14]  
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Dex, almost uniformly, increased the incidence of cataracts and IOP elevation. Even 
though, other adverse events were measurable in some RCTs (such as vitreous 
hemorrhage, retinal tear, retinal detachment, vitreous loss, endophthalmitis, hypotony, 
and complication of device insertion),  it were uncommon. [5] Ozurdex
®
 can be used in 
patients with recent stroke or heart attack, however, it is contraindicated if the anterior 
segment is not compartmentalized from the posterior segment, because of implant 
migration to the anterior chamber in case of disruption of the posterior lens capsule or 
zonular dehiscence. [23]  
Cataract formation happened more in Dex treatment groups, after the first year of 
treatment, (comparable to sham, bevacizumab alone and laser alone). Cataract surgery 
was performed between 18 and 30 months in MEAD study, and after surgery marked 
mean visual gain was seen, in almost studies. OZDRY study (fixed-dose versus PRN) 
showed that percentage of cataract surgery was higher in PRN group (10.2% versus 
2.9%). [22] 
Increases in IOP was consistent in every RCT and it peaked 2 months after each 
injection of Dex. [5][22] One case of glaucoma filtering surgery was described in 
MEAD study and laser trabeculoplasty was needed in one eye from each group (Dex 
and Bevacizumab group) in Bevordex Study. In other studies, the elevations in IOP 
were managed with IOP-lowering medication or observation. Additionally, MEAD 
study proved that there was no cumulative effect of Dex implant. 
Comparative studies between TA plus laser and laser alone demonstrated that combined 
group had greater improvements in BCVA than laser alone, and proved that TA plus 
laser may be a more cost-effective therapy than ranibizumab and laser in pseudophakic 
patients with DME. [20] [14] 
Different corticosteroids (Dex, FA and TA) have different pharmacologic and 
pharmacokinetic profiles, since they activate different patterns of gene expression in 
human trabecular meshwork cell lines. The reason why Dex may have reduced risk of 
IOP increases and cataract progression than FA and TA is related with its less lipophilic 
profile and does not accumulate to the same extend in trabecular meshwork and lens. [5] 
Anti-VEGF agents (such as ranibizumab or bevacizumab) have greater results in BCVA  
than corticosteroids agents, and less cataract formation or increased IOP results. 
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However, Dex implant provide less injections for the treatment of DME and some 
studies, which included patients with both eyes enrolled (one treated with Dex implant 
and the other with bevacizumab implant), proved that patients preferred Dex implant, 
despite cataract surgery  (33% preferred bevacizumab, 46% preferred the Dex implant, 
and 21% had no preference (P>0.1) ). [24][14] A higher cost of Dex implants compared 
to anti-VEGF implants is balanced by the reduced  need of Dex injections, thus, leading 
to a lower final cost. Despite the collateral cost of cataract surgery, Dex treatment is 
probably more cost-effective than anti-VEGF. 
This review has some limitations, such as a small number of studies involved and the 
validity of studies wasn’t improved by assessing the quality of trials using the Cochrane 
risk of bias tables. This review is not a meta-analysis or a systematic review, then, is 
less effective to compare different studies. It included six studies that compared Dex 
implant with sham, bevacizumab and laser therapy, but did not included comparative 
studies between different corticosteroids (Dex, FA and TA) or between other steroid 
and anti-VEGF agent or laser therapy. Furthermore, the studies are fairly heterogeneous, 
with inclusion and exclusion different criteria, different baseline characteristics, follow-
up periods, methods for recording IOP rise, cataract formation and also threshold values 
of cataract surgery. Therefore, strict data treatment are needed to compare different 
studies stringently and produce reliable and comparable results.  
Nowadays, Ozurdex
®
 may be a promising new treatment option for eyes with persistent 
DME and can be useful in eyes with chronic edema or eyes that do not respond to anti- 
VEGF therapy. It may also be preferred in pseudophakic eyes or in those eyes about to 
undergo cataract surgery, in vitrectomized eyes or in patients who have barriers to 
monthly treatment regimen.  
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llm
en
t;  
p
o
o
rly
 co
n
tro
lled
 d
iab
etes (d
efin
ed
 as a h
em
o
g
lo
b
in
 A
1
c lev
el ˃
1
3
%
); m
o
d
erate o
r sev
ere g
lau
co
m
a in
 th
e stu
d
y
 ey
e. 
In
clu
sio
n
 criteria: B
C
V
A
 b
etw
een
 3
4
 an
d
 6
8
 letters (2
0
/2
0
0
-2
0
/5
0
); fo
v
ea-in
v
o
lv
ed
 M
E
 an
d
 h
ad
 b
een
 p
rev
io
u
sly
 treated
 w
ith
 m
ed
ical 
o
r laser th
erap
y
 w
ere en
ro
lled
 in
 th
e stu
d
y
. 
E
x
clu
sio
n
 criteria: treatm
en
t w
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 in
trav
itreal an
ti-V
E
G
F
 w
ith
in
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 m
o
n
th
s o
f stu
d
y
 en
try
, treatm
en
t w
ith
 in
trav
itreal triam
cin
o
lo
n
e 
w
ith
in
 6
 m
o
n
th
s o
f stu
d
y
 en
try
, cu
rren
t u
se o
r an
ticip
ated
 u
se o
f sy
stem
ic stero
id
s d
u
rin
g
 th
e stu
d
y
; u
n
co
n
tro
lled
 d
iab
etes (g
ly
co
sy
lated
 
h
em
o
g
lo
b
in
 [H
b
A
1
c] >
1
0
%
) o
r o
th
er sy
stem
ic d
isease;  g
lau
co
m
a. 
In
clu
sio
n
 a
n
d
 E
x
clu
sio
n
 criter
ia
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 Study  Improvement Similar No improvement 
Sham 
control 
MEAD study 
(Boyer et al) 
2014 
BCVA ×   
CRT √   
(Haller et al) 
2010 
BCVA ×  
(90 days) 
 
×  
(180 days) 
CRT √   
Bevacizumab 
control 
(Maturi et al) 
2015 
BCVA  ×  
CRT √   
The 
BEVORDEX 
Study (Gillies 
et al) 2014 
BCVA 
 ×  
CRT 
√   
Laser 
control 
OZLASE study 
(Heng et al) 
2015 
BCVA  ×  
CRT √   
Placid Study 
(Callanan et al) 
2013 
BCVA × 
 (up to 9 months) 
× 
(12 months)  
 
CRT 
√   
Table 7.  Overview of results 
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Figure 1. Treatment of DME flow diagram.  
 
1IOP check after 4–8 weeks of initial treatment, especially in eyes with established glaucoma or ocular hypertension 
or previous history of steroid-induced ocular hypertension. [22] 
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Laser therapy 
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Pseudophakic 
lens? 
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Anti-Vegf (> 
injections)  
refractory or 
incomplete 
response 
Steroids (< 
injections) 
Fenofibrate 
Control of blood 
pressure, blood 
sugars 
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